A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M15.7,14.7c0.1,0.1,0.2,0.1,0.3,0.1c0,0,0,0,0.1,0c0.1,0,0.2-0.1,0.3-0.2l1.9-5.7c0.1-0.2,0-0.4-0.2-0.4%20c-1-0.4-2.2-0.4-3.3-0.2c-1.1,0.2-2.1,0.7-2.9,1.5c-0.1,0.1-0.1,0.3,0,0.5L15.7,14.7z'/%3e%3cpath%20style='&st5;'%20d='M22.5,20.3l-6.5-4.1l-5.1-5.6c-0.1-0.1-0.3-0.1-0.5,0c-2.1,1.8-2.9,4.5-2.3,7.2c0.8,3.7,4.3,6.4,8.1,6.4%20c0,0,0,0,0,0c0.4,0,0.9,0,1.3-0.1c2.1-0.4,3.9-1.5,5-3.3c0-0.1,0.1-0.2,0-0.3C22.6,20.4,22.6,20.3,22.5,20.3z%20M17.4,23.4%20c-0.4,0.1-0.8,0.1-1.2,0.1c0,0,0,0,0,0c-3.5,0-6.7-2.5-7.5-5.9c-0.5-2.3,0.2-4.7,1.9-6.3l4.9,5.4c0,0,0,0,0.1,0.1l6.3,3.9%20C20.8,22.1,19.3,23.1,17.4,23.4z'/%3e%3cpath%20style='&st5;'%20d='M24.1,14.2c-0.1-0.3-0.2-0.7-0.3-1c0,0,0-0.1,0-0.1c-0.3-0.7-0.7-1.4-1.1-2c0,0,0-0.1-0.1-0.1c0,0,0,0,0,0%20c-0.5-0.5-1-1-1.6-1.4c0,0,0,0,0,0c0,0-0.1-0.1-0.1-0.1c-0.5-0.3-0.9-0.5-1.5-0.7C19.2,8.7,19,8.8,19,9l-2.3,6.4c0,0,0,0,0,0l0,0%20c0,0.1,0,0.3,0.1,0.4l5.9,3.7c0.1,0,0.1,0.1,0.2,0.1c0.1,0,0.2-0.1,0.3-0.2C24.2,17.9,24.5,16,24.1,14.2z%20M20.5,17.3l2.9-3.3%20c0,0.1,0.1,0.2,0.1,0.4c0.1,0.6,0.2,1.1,0.1,1.7l-1.9,2.1L20.5,17.3z%20M18.6,16.1l3.8-4.3c0.3,0.4,0.6,0.9,0.8,1.4l-3.3,3.7%20L18.6,16.1z%20M19.5,9.5c0.3,0.1,0.5,0.2,0.8,0.4l-1.5,1.7L19.5,9.5z%20M18.1,13.3l2.7-3c0.4,0.3,0.8,0.6,1.1,1L18,15.8l-0.6-0.4%20L18.1,13.3z%20M22.8,18.8l-0.5-0.3l1.1-1.2C23.3,17.8,23.1,18.3,22.8,18.8z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
11/6/2026
BiosimilarsBreakingCataractDry EyeIOLPharmaRetinaRevenueSurgicalThyroid Eye Disease
Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane
Regeneron of Tarrytown, New York, reported Oct. 30 that its Q3-2026 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was just under $1.1 billion, a 1 perc...
11/6/2026
BreakingPharma
Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs
Nashville, Tennessee-based Harrow reported Nov. 2 that it had launched HarrowRx, allowing eye care providers to prescribe all of Harrow’s branded products within their electronic medical record (EM...
11/6/2026
BreakingIndustryPharmaPresbyopia
Lenz Announces Plans for Major Layoffs, CEO Switch
Lenz Therapeutics, of San Diego, California, announced Oct. 28 a strategic reorganization to reduce projected 2027 annual operating expenses by over 50 percent as it continues to roll out Vizz, its...
11/6/2026
BiosimilarsBreakingRegulationRetina
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane
Sweden’s Xbrane Biopharma announced Oct. 27 that the US FDA had approved its ranibizumab (Lucentis) biosimilar, to be branded Lucamzi in the US. It was approved to treat wet age-related macular deg...
11/6/2026
BreakingCataractFundingMyopiaRefractive
Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness
World leaders, international agencies, and private sector partners met in St. John’s, the capital of Antigua and Barbuda, on Nov. 2 at the Global Summit for Eye Health, an event organized by the In...
11/6/2026
BiosimilarsBreakingEuropeRegulationRetina
Ranibizumab Biosimilar from Accord Gains Positive CHMP Opinion
UK-based Accord Healthcare announced Oct. 15 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended approval for Fovlussea, its proposed biosimil...
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cpath%20style='&st2;'%20d='M19.2,10.1c-1.3,0-2.6,0.7-3.4,1.8c-0.8-1.1-2-1.8-3.4-1.8c-2.3,0-4.2,2.1-4.2,4.6c0,0.6,0.1,1.1,0.3,1.7%20c0,0,0,0,0,0c0,0.1,0.1,0.2,0.1,0.3c0.2,0.5,0.5,0.9,0.8,1.3c0.7,0.8,5.9,5.6,6.1,5.8c0.1,0.1,0.2,0.1,0.3,0.1c0.1,0,0.2,0,0.3-0.1%20c0.2-0.2,5.6-5.2,6.4-6.1c0.6-0.8,1-1.9,1-2.9C23.4,12.1,21.5,10.1,19.2,10.1z%20M12.4,10.9c1.2,0,2.4,0.8,3,2%20c0.1,0.1,0.2,0.2,0.4,0.2c0.2,0,0.3-0.1,0.4-0.2c0.6-1.2,1.7-2,3-2c1.9,0,3.4,1.7,3.4,3.8c0,0.4-0.1,0.9-0.2,1.3c0,0,0,0,0,0h-4.7%20c-0.2,0-0.3,0.1-0.4,0.2l-0.8,1.9l-2.5-4.7c-0.1-0.1-0.2-0.2-0.4-0.2c-0.1,0-0.3,0.1-0.4,0.2L11.5,16H9.2C9.1,15.6,9,15.1,9,14.7%20C9,12.6,10.6,10.9,12.4,10.9z%20M15.8,22.9c-1.1-1-5.2-4.8-5.7-5.5c-0.2-0.2-0.3-0.4-0.4-0.6h2.1c0.1,0,0.3-0.1,0.4-0.2l1.4-2.2%20l2.5,4.8c0.1,0.1,0.2,0.2,0.4,0.2c0,0,0,0,0,0c0.2,0,0.3-0.1,0.4-0.2l1.1-2.4H22c-0.1,0.1-0.1,0.2-0.2,0.3%20C21.2,17.8,17.5,21.3,15.8,22.9z'/%3e%3cpath%20style='&st2;'%20d='M16,30.6C8,30.6,1.4,24,1.4,16C1.4,7.9,8,1.4,16,1.4S30.6,7.9,30.6,16C30.6,24,24,30.6,16,30.6z%20M16,2.4%20C8.5,2.4,2.4,8.5,2.4,16S8.5,29.6,16,29.6S29.6,23.5,29.6,16S23.5,2.4,16,2.4z'/%3e%3c/g%3e%3c/svg%3e)
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3cpath%20style='&st5;'%20d='M13.7,10h2.1c0.2,0,0.4-0.2,0.4-0.4S16,9.2,15.8,9.2h-2.1c-0.2,0-0.4,0.2-0.4,0.4S13.4,10,13.7,10z'/%3e%3cpath%20style='&st5;'%20d='M18.3,10.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4s0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4S18.6,10.3,18.3,10.3z'%20/%3e%3cpath%20style='&st5;'%20d='M18.3,11.3h-4.7c-0.2,0-0.4,0.2-0.4,0.4c0,0.2,0.2,0.4,0.4,0.4h4.7c0.2,0,0.4-0.2,0.4-0.4%20C18.7,11.5,18.6,11.3,18.3,11.3z'/%3e%3cpath%20style='&st5;'%20d='M21.9,19.2h1.4c0.6,0,1.1-0.5,1.1-1.1v-1.4c0-0.6-0.5-1.1-1.1-1.1h-1.4c-0.6,0-1.1,0.5-1.1,1.1V17h-3.3%20l-1.2-1.2c0,0,0,0,0,0v-2.1H19c1,0,1.8-0.8,1.8-1.8V9.4c0-1-0.8-1.8-1.8-1.8H13c-1,0-1.8,0.8-1.8,1.8V12c0,1,0.8,1.8,1.8,1.8h2.6%20v2.1c0,0,0,0,0,0L14.4,17h-1.9v-0.3c0-0.6-0.5-1.1-1.1-1.1H8.7c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h2.8%20c0.6,0,1.1-0.5,1.1-1.1v-0.3h1.9l1.2,1.2v1.9h-0.3c-0.6,0-1.1,0.5-1.1,1.1v1.4c0,0.6,0.5,1.1,1.1,1.1h1.4c0.6,0,1.1-0.5,1.1-1.1%20V23h3.1c0.2,0.8,0.9,1.4,1.7,1.4c1,0,1.8-0.8,1.8-1.8c0-1-0.8-1.8-1.8-1.8c-0.8,0-1.6,0.6-1.7,1.4h-3.1v-0.3%20c0-0.6-0.5-1.1-1.1-1.1h-0.3V19l1.2-1.2h3.3v0.3C20.8,18.7,21.3,19.2,21.9,19.2z%20M23.6,18.1c0,0.2-0.1,0.3-0.3,0.3h-1.4%20c-0.2,0-0.3-0.1-0.3-0.3v-1.4c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3V18.1z%20M16.8,17.4L16,18.2l-0.8-0.8l0.8-0.8%20L16.8,17.4z%20M19,13H13c-0.6,0-1-0.5-1-1V9.4c0-0.6,0.5-1,1-1H19c0.6,0,1,0.4,1,1V12C20,12.5,19.5,13,19,13z%20M15,21.9%20c0-0.2,0.1-0.3,0.3-0.3h1.4c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3h-1.4c-0.2,0-0.3-0.1-0.3-0.3V21.9z%20M8.4,16.7%20c0-0.2,0.1-0.3,0.3-0.3h2.8c0.2,0,0.3,0.1,0.3,0.3v1.4c0,0.2-0.1,0.3-0.3,0.3H8.7c-0.2,0-0.3-0.1-0.3-0.3V16.7z%20M21.6,22.6%20c0-0.6,0.4-1,1-1c0.6,0,1,0.4,1,1c0,0.6-0.4,1-1,1C22.1,23.6,21.6,23.2,21.6,22.6z'/%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Extensive analysis
- Integrated disease models
- Expert-based segmentation
Integrate and reconcile
- Continuous feedback loop
- Integration of survey data
- Triangulation of results
- Cross-model analysis
- Reconciliation to company revenues
Produce products covering key medical markets
- Medical devices
- Drugs/biologics
- Equipment
- Providers
Gather feedback
- New market insights
- Client requests
- Landmark study evaluations
Incorporate and revise
- Forecasting models
- Analytical tools and methods
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.